Clinical Meaningfulness of Response to Tanezumab in Patients with Chronic Low Back Pain: Analysis From a 56-Week, Randomized, Placebo- and Tramadol-Controlled, Phase 3 Trial.
John D MarkmanThomas J SchnitzerSerge PerrotSaid R BeydounSeiji OhtoriLars ViktrupRuoyong YangCandace BramsonChristine R WestKenneth M VerburgPublished in: Pain and therapy (2022)
gov: NCT02528253.